Please assess the completion status of the following clinical trial:

Trial Title: Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 ≤ 75 years of age~* Scheduled amputation at or above ankle joint, or a more proximal location but below or through the knee joint~* Documented severe lower extremity peripheral artery occlusive disease confirmed by clinical symptoms of critical limb ischemia and:~  * Frankly gangrenous tissue that merits amputation or~ * Angiographic evidence of occlusive peripheral artery disease within one month of screening~* Participant or legal representative signs informed consent~* Willingness to follow study instructions and follow-up visits~Exclusion Criteria:~* No informed consent is obtained~* If medically inappropriate to administer 250 mL colloidal solution daily for 4 consecutive days~* Uncontrolled hypertension (BP \> 160/90 mm Hg) despite 2 antihypertensive meds or BP \> 180/100 mm Hg if untreated~* Severe liver dysfunction defined by Total Bilirubin \> 3 mg/dL or twice the normal limit of serum AST or ALT~* Symptomatic CVD diagnosed w/ in last 6 months or known high grade carotid stenosis~* Any severe or unstable medical condition that might interfere w/ the evaluation of study medication~* Cardiogenic shock (cardiac index \< 2 L/min/m2, PCWP \> 18 mm Hg)~* Amputation above knee joint or below ankle joint~* Any amputation whereby primary skin closure not technically feasible~* Candidate for percutaneous or surgical revascularization~* Cardiac failure defined by a NY class III/IV or left ventricular ejection fraction \< 30%~* Life expectancy \< 60 days~* Systemic mastocytosis~* Previously demonstrated beef product allergy~* Myocardial infarction w/ in 30 days~* Participation in another trial w/ in last 30 days~* Woman who is pregnant or breastfeeding~* Amputation with known infection at site of skin closure~* Renal dysfunction requiring dialysis, or serum creatinine level 2.5 mg/dL~* Peripheral vascular occlusion from cardio arterial emboli~* Uncontrolled diabetes blood glucose ≥ 400 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Hemoglobin glutamer 250 - bovine
- 2 (Type: ACTIVE_COMPARATOR): 6% Hydroxyethylstarch

Based on this trial design, predict the completion outcome and termination type (if applicable).